BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:remibrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of remibrutinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06868212-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06868212)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Ear
 ly Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Co
 ntrolled by Second Generation H1-antihistamines\nEstimated primary complet
 ion: 22 February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/remibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06868212
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799000-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06799000)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva (RECHARGE 1)\nEstimated primary completion: 17 May 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06799000
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840392-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270603
DTEND;VALUE=DATE:20270604
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06840392)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Ph
 ase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in 
 Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppura
 tiva\nEstimated primary completion: 3 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/remibrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06840392
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865651-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270823
DTEND;VALUE=DATE:20270824
SUMMARY:remibrutinib: Phase 2 readout est. (NCT06865651)
DESCRIPTION:remibrutinib\, phase 2\, Chronic Spontaneous Urticaria.\nStudy:
  Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its
  Mechanism of Action in Participants With Chronic Urticaria\nEstimated pri
 mary completion: 23 August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/remibrutinib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06865651
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855276-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20271129
DTEND;VALUE=DATE:20271130
SUMMARY:remibrutinib: Phase 1 readout est. (NCT07855276)
DESCRIPTION:remibrutinib\, phase 1\, Hidradenitis Suppurativa.\nStudy: A St
 udy to Explore the Tissue Level Effects of Remibrutinib in Adults With Mod
 erate to Severe HS\nEstimated primary completion: 29 November 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07855276
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681271-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20271207
DTEND;VALUE=DATE:20271208
SUMMARY:remibrutinib: Phase 2 readout est. (NCT07681271)
DESCRIPTION:remibrutinib\, phase 2.\nStudy: A Phase 2 Study to Investigate 
 the Efficacy\, Safety and Tolerability of Remibrutinib (LOU064) in Adult P
 atients With Papulopustular Rosacea (PPR)\nEstimated primary completion: 7
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remib
 rutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07681271
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816328-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20280524
DTEND;VALUE=DATE:20280525
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07816328)
DESCRIPTION:remibrutinib\, phase 3\, Chronic Spontaneous Urticaria.\nStudy:
  Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm
  in Adult Patients With Chronic Spontaneous Urticaria Inadequately Control
 led by H1-antihistamines Within 24 Weeks\nEstimated primary completion: 24
  May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7816328
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811869-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20290226
DTEND;VALUE=DATE:20290227
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07811869)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: A Study to Evaluate Efficacy\, 
 Safety\, and Tolerability of Remibrutinib in Adult Participants With Sever
 e Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary completion:
  26 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/re
 mibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07811869
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768371-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20290330
DTEND;VALUE=DATE:20290331
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07768371)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: A 52-week Study of Remibrutinib
  in IgE-mediated Food Allergy\nEstimated primary completion: 30 March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07768371
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846281-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06846281)
DESCRIPTION:remibrutinib\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy a
 nd Safety of Remibrutinib After Switching From Ocrelizumab in Participants
  Living With Relapsing Multiple Sclerosis.\nEstimated primary completion: 
 25 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remibru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06846281
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07700056-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20291219
DTEND;VALUE=DATE:20291220
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07700056)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: A Study to Evaluate Efficacy\, 
 Safety and Tolerability of Remibrutinib in Adult Participants With Severe 
 Chronic Pruritus of Unknown Origin (CPUO)\nEstimated primary completion: 1
 9 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remi
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07700056
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222956-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20301030
DTEND;VALUE=DATE:20301031
SUMMARY:remibrutinib: Phase 2 readout est. (NCT07222956)
DESCRIPTION:remibrutinib\, phase 2\, Multiple Sclerosis.\nStudy: A Study of
  Remibrutinib Using MR Imaging in Relapsing or Progressive MS\nEstimated p
 rimary completion: 30 October 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/remibrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07222956
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225504-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20301203
DTEND;VALUE=DATE:20301204
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07225504)
DESCRIPTION:remibrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive
  Multiple Sclerosis\nEstimated primary completion: 3 December 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07225504
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665437-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20311015
DTEND;VALUE=DATE:20311016
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07665437)
DESCRIPTION:remibrutinib\, phase 3\, Hidradenitis Suppurativa.\nStudy: An E
 xtension Study to Assess Safety and Efficacy of Remibrutinib in Participan
 ts With Moderate to Severe HS\nEstimated primary completion: 15 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07665437
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07456891-1415@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20330130
DTEND;VALUE=DATE:20330131
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07456891)
DESCRIPTION:remibrutinib\, phase 3.\nStudy: Remibrutinib Open Label Roll-ov
 er Post-trial Access Protocol\nEstimated primary completion: 30 January 20
 33. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07456891
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
